These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28299742)

  • 21. Computational Approaches to Matrix Metalloprotease Drug Design.
    Singh T; Jayaram B; Adekoya OA
    Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
    Cao R; Liu M; Yin M; Liu Q; Wang Y; Huang N
    J Chem Inf Model; 2012 Oct; 52(10):2730-40. PubMed ID: 22992059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scaffold-based Screening and Molecular Dynamics Simulation Study to Identify Two Structurally Related Phenolic Compounds as Potent MMP1 Inhibitors.
    Patra S; Saravanan P; Das B; Subramanian V; Patra S
    Comb Chem High Throughput Screen; 2020; 23(8):757-774. PubMed ID: 32342802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.
    Nuti E; Cuffaro D; Bernardini E; Camodeca C; Panelli L; Chaves S; Ciccone L; Tepshi L; Vera L; Orlandini E; Nencetti S; Stura EA; Santos MA; Dive V; Rossello A
    J Med Chem; 2018 May; 61(10):4421-4435. PubMed ID: 29727184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
    Kalva S; Agrawal N; Skelton AA; Saleena LM
    Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
    Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix-based Molecular Descriptors for Prospective Virtual Compound Screening.
    Grisoni F; Reker D; Schneider P; Friedrich L; Consonni V; Todeschini R; Koeberle A; Werz O; Schneider G
    Mol Inform; 2017 Jan; 36(1-2):. PubMed ID: 27650559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
    Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
    Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
    Spicer TP; Jiang J; Taylor AB; Choi JY; Hart PJ; Roush WR; Fields GB; Hodder PS; Minond D
    J Med Chem; 2014 Nov; 57(22):9598-611. PubMed ID: 25330343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
    Kalva S; Vinod D; Saleena LM
    J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B; Matter H
    J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking.
    Wang Y; Yang L; Hou J; Zou Q; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Feb; 37(3):649-670. PubMed ID: 29380672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening.
    Szaszkó M; Hajdú I; Flachner B; Dobi K; Magyar C; Simon I; Lőrincz Z; Kapui Z; Pázmány T; Cseh S; Dormán G
    Mol Divers; 2017 Feb; 21(1):175-186. PubMed ID: 28070724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Virtual Screening.
    Li Q; Shah S
    Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Novel Natural Product Inhibitors against Matrix Metalloproteinase 9 Using Quantum Mechanical Fragment Molecular Orbital-Based Virtual Screening Methods.
    Lim H; Hong H; Hwang S; Kim SJ; Seo SY; No KT
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
    Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
    Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.